Diabetes Research and Clinical Practice
Volume 75, Issue 1 , Pages 35-41 , January 2007

Chronic renal failure in diabetic patients increases lipid risk factors for atherosclerosis

Received 28 September 2005 ,Accepted 22 May 2006.

References 

  1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diab. Med. 1997;14:S1–S85
  2. Cornitescu G, Mota M, Mota E, Stanescu L. Clinical considerations concerning progressive diabetic renal diseases. Severe complications of early onset diabetes mellitus. Rom. J. Int. Med. 2003;41:53–60
  3. Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lipoproteins and diabetic microvascular complications. Curr. Pharm. Dis. 2004;10:3395–3418
  4. Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int. Suppl. 1999;71:S22–S24
  5. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol. Dial. Transplant. 1998;13:2833–2841
  6. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diab. Care. 1992;15:820–825
  7. Erciyas F, Taneli F, Arslan B, Uslu Y. Glycemic control, oxidative stress, and lipid profile in children with type 1 diabetes mellitus. Arch. Med. Res. 2004;35:134–140
  8. Laakso M, Pyorala K, Sarlund H, Voutilainen E. Lipid and lipoprotein abnormalities associated with coronary heart disease in patients with insulin-dependent diabetes mellitus. Arteriosclerosis. 1986;6:679–684
  9. Rossi A, Bonfante L, Giacomini A, Calabro A, Rossi G, Saller A, et al. Carotid artery lesions in patients with nondiabetic chronic renal failure. Am. J. Kidney Dis. 1996;27:58–66
  10. Haaber AB, Eidemak I, Jensen T, Feldt-Rasmussen B, Strandgaard S. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J. Am. Soc. Nephrol. 1995;5:1581–1584
  11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diab. Care 20 (1997) 183–1197.
  12. Gernand K, Hajek E. Comparative study on quantitative cerebrospinal fluid and urinary protein determination with a modified Exton reagent. Dtsch Gesundheitsw. 1966;21:510–513
  13. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin. Chem. 1982;28:1379–1388
  14. Bartlett GR. Phosphorus assay in column chromatography. J. Biol. Chem. 1959;234:466–468
  15. Assmann G, Jabs HU, Kohnert U, Nolte W, Schriewer H. LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate. Clin. Chim. Acta. 1984;140:77–83
  16. Wikinski RL, Schreier LE, Rosental SB. New method for isolating and quantifying intermediate and beta-very-low-density lipoprotein cholesterol. Clin. Chem. 1991;37:1913–1916
  17. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of clorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal. Biochem. 1989;180:242–247
  18. Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler. Thromb. Vasc. Biol. 1996;16:1243–1249
  19. Alebiosu CO, Odusan O, Familoni OB, Jaiyesimi AE. Cardiovascular risk factors in type 2 diabetic Nigerians with clinical diabetic nephropathy. Cardiovasc. J. S. Afr. 2004;15:124–128
  20. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 285 (2001) 2486–2497.
  21. Kimoto E, Shoji T, Emoto M, Miki T, Tabata T, Okuno Y, et al. Effect of diabetes on uremic dyslipidemia. J. Atheroscler. Thromb. 2002;9:305–313
  22. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am. J. Kidney Dis. 1993;21:573–592
  23. Gonzalez AI, Schreier L, Elbert A, Berg G, Beresan H, Lopez G, et al. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients. Metabolism. 2003;52:116–121
  24. Joven J, Villabona C, Vilella E. Pattern of hyperlipoproteinemia in human nephrotic syndrome: influence of renal failure and diabetes mellitus. Nephron. 1993;64:565–569
  25. Kaysen GA, Hoye E, Jones H, van Tol A, Joles JA. Effect of oncotic pressure on apolipoprotein A-I metabolism in the rat. Am. J. Kidney Dis. 1995;26:178–186
  26. Jüngst D, Caselmann WH, Kutschera P, Weisweiler P. Relation of hyperlipidemia in serum and loss of high density lipoproeins in urine on the nephrotic syndrome. Clin. Chim. Acta. 1987;168:159–167
  27. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J. Lipid Res. 1968;9:155–167
  28. Macknes M, Abbot C, Arrol S, Durrington P. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low density lipoprotein oxidation. Biochem. J. 1993;294:829–834
  29. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. J. Clin. Invest. 1995;96:2882–2891
  30. Navab M, Hama SY, Hough GP, Hedrick CC, Sorenson R, La Du BN, et al. High density associated enzymes: their role in vascular biology. Curr. Opin. Lipidol. 1998;9:449–456
  31. Sanguineti S, Brites F, Fasulo V, Verona J, Elbert A, Wikinski R, et al. HDL oxidability and its protective effect against LDL oxidation in type 2 diabetic patients. Diab. Nutr. Metab. 2001;14:21–31
  32. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism. 1998;47:598–602
  33. Gomo ZA, Henderson LO, Myrick JE. High-density lipoprotein apolipoproteins in urine: I. Characterization in normal subjects and in patients with proteinuria. Clin. Chem. 1988;34:1775–1780
  34. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J. Clin. Invest. 1993;91:1743–1752

PII: S0168-8227(06)00228-2

doi: 10.1016/j.diabres.2006.05.011

Diabetes Research and Clinical Practice
Volume 75, Issue 1 , Pages 35-41 , January 2007

Article Tools

* Image Usage & Resolution